The substantia nigra — Latin for black substance — lives in the midbrain. It is black under the microscope because of neuromelanin, a pigment that accumulates as a byproduct of dopamine metabolism. The pigment is visible to the unaided eye on a fresh brain section. The structure looks like a thin curved band of dark tissue tucked into the midbrain.
The substantia nigra is dopamine's first home. The neurons there project upward through the nigrostriatal pathway to the basal ganglia, supplying the dopamine that lets you initiate and refine your movements. We will visit the basal ganglia in Stage 5 and see how dopamine controls action selection there. For now, hold this fact: the substantia nigra supplies the motor dopamine system.
When the substantia nigra dies, you lose the ability to initiate movement smoothly. This is Parkinson's disease. The clinical picture is the cumulative loss of dopaminergic neurons: the resting tremor, the bradykinesia (slowness), the rigidity, the masked face, the shuffling gait. These symptoms emerge gradually because the brain compensates for the loss until compensation fails.
Here is the striking number. By the time Parkinson's symptoms become clinically obvious, roughly 60 to 80 percent of substantia nigra neurons are already gone. The brain has been losing them for years. The patient and family notice when compensation breaks down — when a hand begins to tremor at rest, when walking pace slows, when the face stops showing emotion. By then, most of the structure has already been lost.
This has clinical implications. The slow course of cell loss means that early Parkinson's may be present years before diagnosis, and biomarker research now focuses on detecting the prodromal phase — REM sleep behavior disorder, hyposmia, constipation, mild bradykinesia — that may precede motor symptoms by a decade.
The treatment for Parkinson's is to replace the missing dopamine with levodopa, which crosses the blood-brain barrier and is converted to dopamine in the surviving neurons. We will return to this at the basal ganglia chapter. For now, when you see a Parkinson's patient with the masked face and shuffling gait, you are seeing the cumulative loss of a small dark structure in the engine room of the brain.